Baolingbao Biology Co., Ltd. Class A

Baolingbao Biology Co., Ltd. Class A

SSZSE:002286
8.30
CNY
+0.06
(+0.73%)
0.38EPS
21.84P/E
3.14BMarket Cap
Oct 29Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.63
2.4
3.21
3.63
4.17
4.83
5.12
5.77
7.41
7.33
7.01
6.48
7.49
7.58
Basic EPS, GAAP
0.12
0.06
0.11
0.13
0.13
0.12
0.1
0.14
0.54
0.36
0.15
0.3
0.41
0.38
Free Cash Flow per Basic Share
-0.18
-0.45
-0.33
0.03
-0.36
-0.11
0.17
0.75
0.3
-0.6
0.36
0.16
0.19
- -
Dividend per Share
0.1
0.03
0.05
0.07
0.1
0.17
0.12
0.07
0.1
0.14
0.14
0.15
0.09
0.08
Book Value per Share
3.88
3.92
4
4.08
4.12
4.17
4.24
4.33
4.88
5.39
5.35
5.52
5.87
6.11
Tangible Book Value per Share
3.58
3.62
3.64
3.69
3.74
3.8
3.88
3.97
4.53
5.05
5.02
5.2
5.57
5.81
Basic Weighted Avg Shares
343
380
372
380
382
358
352
356
373
370
360
371
367
374
Sales/Revenue/Turnover
901
911
1,196
1,377
1,593
1,730
1,805
2,055
2,765
2,713
2,524
2,402
2,751
2,835
Operating Margin (%)
2.87
-0.29
2.14
2.72
3.55
4.13
4.18
3.54
8.4
6.18
3.65
6.73
6.86
6.53
Depreciation Expense
48
50
56
78
77
84
98
96
105
106
123
120
120
- -
Net Income, GAAP
41
23
41
49
50
43
35
50
202
133
54
111
151
141
Effective Tax Rate (%)
14.7
13.09
14.35
15.78
14
18.78
23.72
16.38
14.85
15.01
17.12
15.22
15.29
15.57
Profit Margin (%)
4.56
2.5
3.42
3.58
3.12
2.48
1.95
2.43
7.29
4.91
2.14
4.63
5.48
4.98
Working Capital
592
377
222
235
208
-58
47
49
195
236
209
234
430
444
LT Debt
- -
- -
- -
- -
- -
11
11
12
27
171
38
1
1
41
Total Equity
1,435
1,448
1,478
1,508
1,525
1,542
1,567
1,599
1,813
2,004
1,983
2,042
2,234
2,326
Return on Invested Capital (%)
2.04
0.73
2.01
2.58
2.91
2.29
1.72
2.6
9.9
5.77
2.22
5.71
6.49
5.67
Return on Capital (%)
3.74
1.7
3.04
3.34
3.29
3.47
2.86
3.11
10.63
6.59
3.04
5.32
6.79
5.98
Return on Common Equity (%)
3.64
1.58
2.8
3.31
3.28
2.8
2.27
3.15
11.81
6.98
2.71
5.52
7.05
6.4

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
115
217
137
LT Borrowings
- -
- -
40
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
381
381
381
Market Capitalization
3,402
3,665
3,140

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
914
1,021
1,041
Cash, Cash Equivalents & STI
277
286
313
Accounts Receivable, Net
268
327
340
Inventories
322
325
324
Total Current Liabilities
485
570
597
Payables & Accruals
- -
- -
- -
ST Debt
115
217
137
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.32%
7.04%
9.41%
Free Cash Flow
-180.76%
-109.69%
19.18%
Net Income, GAAP
38.35%
70.47%
35.5%
Sales/Revenue/Turnover
9.3%
7.09%
14.54%
Total Cash Common Dividend
13.12%
11.74%
-42.27%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
551
634
648
568
2,402
2025
685
714
- -
625
2,751
2026
748
748
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
0.12
0.09
0.03
0.3
2025
0.14
0.11
- -
0.04
0.41
2026
0.14
0.08
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.09
0.01
0.01
0.04
0.15
2025
0.01
0.07
- -
- -
0.09
2026
- -
0.01
- -
- -
- -

Company Description

CEO
Qiang Wang
Full Time Employees
1,505
Sector
Consumer non-durables
Industry
Food: specialty/candy
Address
No. 1, East Outer Ring Road Dezhou SD China 251200
IPO Date
Sep 2, 2009
Website
blb-cn.com
Business
Baolingbao Biology Co., Ltd. (002286.SZ) researches, develops, manufactures and sells functional sugars and related ingredients primarily from corn in China and internationally; its core products include prebiotics such as isomaltooligosaccharide, galacto-oligosaccharide, fructooligosaccharide and xylooligosaccharide; dietary fibers including polydextrose and resistant dextrin; sugar alcohols and sweeteners such as erythritol, allulose, trehalose, crystalline fructose and maltose; starch sugars comprising maltodextrin, glucose syrup, high fructose corn syrup, solid and liquid starch sugar series; and byproducts like corn steep liquor, corn gluten meal and modified starches, which serve applications in dairy, beverages, snacks, health supplements, confectionery, daily chemicals and animal nutrition. Founded in 1997 and headquartered in Yucheng, Shandong Province, China, the company, a national high-tech enterprise and manufacturing single champion, listed on the Shenzhen Stock Exchange A-shares in 2009 and operates as a global provider of functional health solutions with exports to international markets. In 2025, Baolingbao Biology won the iSEE global innovation award at Foodaily for its high-purity human milk oligosaccharide Supmos production technology and showcased products prominently at FIC 2025; the company also reported 2024 net profit exceeding CNY100 million with over 100% growth and improved gross margins.